| Understanding the economic impact of intravascular ultrasound (IVUS) A Alberti, P Giudice, A Gelera, L Stefanini, V Priest, M Simmonds, C Lee, ... The European Journal of Health Economics 17, 185-193, 2016 | 72 | 2016 |
| Increased hospital length of stay attributable to Clostridium difficile infection in patients with four co-morbidities: an analysis of hospital episode statistics in four … C Eckmann, M Wasserman, F Latif, G Roberts, A Beriot-Mathiot The european Journal of Health economics 14, 835-846, 2013 | 57 | 2013 |
| Clinical and economic impact of a potential switch from 13-valent to 10-valent pneumococcal conjugate infant vaccination in Canada M Wilson, M Wasserman, T Jadavi, M Postma, MC Breton, F Peloquin, ... Infectious diseases and therapy 7, 353-371, 2018 | 38 | 2018 |
| Twenty-year public health impact of 7-and 13-valent pneumococcal conjugate vaccines in US children M Wasserman, R Chapman, R Lapidot, K Sutton, D Dillon-Murphy, ... Emerging infectious diseases 27 (6), 1627, 2021 | 33 | 2021 |
| Ten year public health impact of 13-valent pneumococcal conjugate vaccination in infants: a modelling analysis R Chapman, K Sutton, D Dillon-Murphy, S Patel, B Hilton, R Farkouh, ... Vaccine 38 (45), 7138-7145, 2020 | 30 | 2020 |
| Review of vaccine effectiveness assumptions used in economic evaluations of infant pneumococcal conjugate vaccine M Wasserman, HL Sings, D Jones, S Pugh, M Moffatt, R Farkouh Expert review of vaccines 17 (1), 71-78, 2018 | 30 | 2018 |
| Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States L Huang, M Wasserman, L Grant, R Farkouh, V Snow, A Arguedas, ... Vaccine 40 (33), 4700-4708, 2022 | 24 | 2022 |
| Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China K Shen, M Wasserman, D Liu, YH Yang, J Yang, GF Guzauskas, ... PLoS One 13 (7), e0201245, 2018 | 24 | 2018 |
| Pneumococcal conjugate vaccine impact on serotype 3: a review of surveillance data HL Sings, BD Gessner, MD Wasserman, L Jodar Infectious diseases and therapy 10, 521-539, 2021 | 22 | 2021 |
| Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico M Wasserman, MG Palacios, AG Grajales, FB Baez/Revueltas, M Wilson, ... Human Vaccines & Immunotherapeutics 15 (3), 560-569, 2019 | 21 | 2019 |
| Clinical and economic burden of pneumococcal disease due to serotypes contained in current and investigational pneumococcal conjugate vaccines in children under five years of age MD Wasserman, J Perdrizet, L Grant, K Hayford, S Singh, P Saharia, ... Infectious Diseases and Therapy 10, 2701-2720, 2021 | 20 | 2021 |
| Estimating the impact of switching from a lower to higher valent pneumococcal conjugate vaccine in Colombia, Finland, and The Netherlands: a cost-effectiveness analysis S Pugh, M Wasserman, M Moffatt, S Marques, JM Reyes, VA Prieto, ... Infectious Diseases and Therapy 9, 305-324, 2020 | 19 | 2020 |
| Dynamic transmission modelling to address infant pneumococcal conjugate vaccine schedule modifications in the UK M Wasserman, A Lucas, D Jones, M Wilson, B Hilton, A Vyse, H Madhava, ... Epidemiology & Infection 146 (14), 1797-1806, 2018 | 18 | 2018 |
| Trends in vaccine investment in middle income countries K Onishchenko, S Hill, M Wasserman, C Jones, M Moffatt, L Ruff, SJ Pugh Human Vaccines & Immunotherapeutics, 2019 | 17 | 2019 |
| Cost-effectiveness analysis of replacing the 10-valent pneumococcal conjugate vaccine (PCV10) with the 13-valent pneumococcal conjugate vaccine (PCV13) in Brazil infants J Perdrizet, CFS Santana, T Senna, RF Alexandre, R Sini de Almeida, ... Human Vaccines & Immunotherapeutics 17 (4), 1162-1172, 2021 | 15 | 2021 |
| Pneumococcal vaccination in children: a systematic review and meta-analysis of cost-effectiveness studies MS Syeed, P Ghule, LM Le, SK Veettil, EK Horn, J Perdrizet, ... Value in Health 26 (4), 598-611, 2023 | 13 | 2023 |
| Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea HY Kim, SB Park, ES Kang, SM Lee, HJ Kim, M Wasserman Human Vaccines & Immunotherapeutics 17 (3), 909-918, 2021 | 13 | 2021 |
| Cost-effectiveness of the pneumococcal conjugate vaccine (10-or 13-valent) versus no vaccination for a national immunization program in Tunisia or Algeria SJ Pugh, MA Fletcher, A Charos, L Imekraz, M Wasserman, R Farkouh Infectious Diseases and Therapy 8, 63-74, 2019 | 13 | 2019 |
| Retrospective impact analysis and cost-effectiveness of the pneumococcal conjugate vaccine infant program in Australia J Perdrizet, YS Lai, S Williams, VA Struwig, M Wasserman Infectious Diseases and Therapy 10, 507-520, 2021 | 12 | 2021 |
| Health and economic impact of routine pediatric pneumococcal immunization programs in Canada: a retrospective analysis MR Wilson, MD Wasserman, MC Breton, F Peloquin, SR Earnshaw, ... Infectious Diseases and Therapy 9, 341-353, 2020 | 11 | 2020 |
Raymond FarkouhPfizerVerified email at pfizer.com
